Table 1.
Comparison of baseline data
| Baseline data | TACE (n = 20) | TACE+AH (n = 34) | TACE+IMRT (n = 18) | χ2 | P |
|---|---|---|---|---|---|
| Age | 0.201 | 0.905 | |||
| < 55 years old | 11 (55.00) | 17 (50.00) | 10 (55.56) | ||
| ≥ 55 years old | 9 (45.00) | 17 (50.00) | 8 (44.44) | ||
| Sex | 4.578 | 0.101 | |||
| Female | 1 (5.00) | 10 (29.41) | 4 (22.22) | ||
| Male | 19 (95.00) | 24 (70.59) | 14 (77.78) | ||
| Pathologic diagnosis | 0.195 | 0.907 | |||
| HCC | 12 (60.00) | 21 (61.76) | 12 (66.67) | ||
| ICC | 8 (40.00) | 13 (38.24) | 6 (33.33) | ||
| Drinking history | 2.848 | 0.241 | |||
| No | 16 (80.00) | 21 (61.76) | 10 (55.56) | ||
| Yes | 4 (20.00) | 13 (38.24) | 8 (44.44) | ||
| Family history | 0.899 | 0.638 | |||
| No | 7 (35.00) | 15 (44.12) | 9 (50.00) | ||
| Yes | 13 (65.00) | 19 (55.88) | 9 (50.00) | ||
| History of hepatitis | 4.665 | 0.097 | |||
| No | 6 (30.00) | 9 (26.47) | 10 (55.56) | ||
| Yes | 14 (70.00) | 25 (73.53) | 8 (44.44) | ||
| Antiviral therapy | 2.430 | 0.297 | |||
| No | 6 (30.00) | 8 (23.53) | 8 (44.44) | ||
| Yes | 14 (70.00) | 26 (76.47) | 10 (55.56) | ||
| Child-Pugh | 3.275 | 0.194 | |||
| A | 11 (55.00) | 18 (52.94) | 14 (77.78) | ||
| B | 9 (45.00) | 16 (47.06) | 4 (22.22) | ||
| Tumor diameter | 6.068 | 0.194 | |||
| ≥ 5 cm | 18 (90.00) | 24 (70.59) | 10 (55.56) | ||
| 3-5 cm | 2 (10.00) | 8 (23.53) | 6 (33.33) | ||
| ≤ 3 cm | 0 (0.00) | 2 (5.88) | 2 (11.11) | ||
| AFP | 2.552 | 0.279 | |||
| Negative | 6 (30.00) | 14 (41.18) | 10 (55.56) | ||
| Positive | 14 (70.00) | 20 (58.82) | 8 (44.44) | ||
| CA125 | 4.314 | 0.116 | |||
| Negative | 14 (70.00) | 16 (47.06) | 13 (72.22) | ||
| Positive | 6 (30.00) | 18 (52.94) | 5 (27.78) | ||
| CA19-9 | 5.278 | 0.071 | |||
| Negative | 12 (60.00) | 10 (29.41) | 9 (50.00) | ||
| Positive | 8 (40.00) | 24 (70.59) | 9 (50.00) |
Note: Abbreviations: TACE, transcatheter arterial chemoembolization; AH, anlotinib hydrochloride; IMRT, intensity-modulated radiotherapy; HCC, hepatocellular-cancer; ICC, intrahepatic cholangiocarcinoma; AFP, alpha-fetoprotein; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9.